Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Cooperating marmosets extend decision-making model of the brain
When a pair of marmosets works together to earn some marshmallow fluff, one of them decides to act only after its brain accumulates enough evidence about what the other is doing, new work shows.
Cooperating marmosets extend decision-making model of the brain
When a pair of marmosets works together to earn some marshmallow fluff, one of them decides to act only after its brain accumulates enough evidence about what the other is doing, new work shows.
Designer synapses edit brain circuits in living animals
The approach could help elucidate relationships between circuit structure and function, as well as the role of natural electrical synapses.
Designer synapses edit brain circuits in living animals
The approach could help elucidate relationships between circuit structure and function, as well as the role of natural electrical synapses.
Role of GABA-A receptors in dup15q syndrome, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 22 June.
Role of GABA-A receptors in dup15q syndrome, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 22 June.